Results 101 to 110 of about 2,738,593 (315)

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

The Predictive Value of Nomogram Model Based on Neutrophil-to-Lymphocyte Ratio (NLR) and Prothrombin Time-International Normalized Ratio (PT-INR)-to-Albumin Ratio (PTAR) for Early Bacterial Intra-Abdominal Infection After Orthotopic Liver Transplantation

Journal of Inflammation Research
Hua-Bin Peng,1 Ying Liu,1 Fei Hou,1 Shuang Zhao,1 Yi-Zhi Zhang,1 Zhi-Ying He,1 Ting-Ting Cui,1 Jing-Yi Liu,1 Hao-Feng Xiong,1 Li-Ying Sun1– 5 1Department of Critical Liver Diseases, National Clinical Research Center for Digestive Diseases, Beijing ...
Peng HB, Liu Y, Hou F, Zhao S, Zhang YZ, He ZY, Cui TT, Liu JY, Xiong HF, Sun LY   +9 more
doaj  

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria

, 2020
Joo Hyun Oh, Dong Hyun Sinn, Gyu‐Seong Choi, Jong Man Kim, Jae‐Won Joh, Tae Wook Kang, Dongho Hyun, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi   +13 more
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Pattern of liver function and clinical profile in COVID-19: A cross-sectional study of 91 patients

, 2020
Abhishek Kumar, Piyush Kumar, Ajit Dungdung, Anitesh Kumar Gupta, Aditya Anurag, Abhinav Kumar   +5 more
openalex   +2 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

von Willebrand factor polymorphism (rs1063856) as a risk factor for portal vein thrombosis in chronic liver diseases

Egyptian Liver Journal
Background Due to its well-established involvement in clot formation, von Willebrand factor (vWF) has been held responsible for decades as a risk factor for arterio-venous thrombosis. It is currently unclear how genetic differences in vWF genes relate to
Isis Samy Bedira, Olfat M. Hendy, Moones Abdelaal, Ashraf A. Basuni, Asma Ebrahim Gaber Koshoo, Alzhraa Alkhatib, Sally S. Mandour   +6 more
doaj   +1 more source

Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus

, 2020
Adriana Cervo, Jovana Milić, Giovanni Mazzola, Filippo Schepis, Salvatore Petta, Thomas Krahn, Bertrand Lebouché, Marc Deschênes, Antonio Cascio, Giovanni Guaraldi, Giada Sebastiani   +10 more
openalex   +2 more sources